The global B-cell lymphoma market size is calculated at USD 5.44 billion in 2025 and is forecasted to reach around USD 10 billion by 2034, accelerating at a CAGR of 7.00% from 2025 to 2034. The North America market size surpassed USD 1.98 billion in 2024 and is expanding at a CAGR of 7.15% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: B-Cell Lymphoma Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. B-Cell Lymphoma Market, by Disease Type
8.1.1. Diffuse Large B-Cell Lymphoma (DLBCL)
8.1.1.1. Market Revenue and Forecast
8.1.2. Follicular Lymphoma (FL)
8.1.2.1. Market Revenue and Forecast
8.1.3. Mantle Cell Lymphoma (MCL)
8.1.3.1. Market Revenue and Forecast
8.1.4. CLL/SLL
8.1.4.1. Market Revenue and Forecast
9.1. B-Cell Lymphoma Market, by Therapy Type
9.1.1. Chemotherapy
9.1.1.1. Market Revenue and Forecast
9.1.2. Monoclonal Antibodies (e.g., rituximab)
9.1.2.1. Market Revenue and Forecast
9.1.3. BTK Inhibitors (e.g., acalabrutinib)
9.1.3.1. Market Revenue and Forecast
9.1.4. Antibody Drug Conjugates (ADCs) (e.g., polatuzumab vedotin, loncastuximab)
9.1.4.1. Market Revenue and Forecast
9.1.5. Bispecific Antibodies (e.g., epcoritamab, glofitamab)
9.1.5.1. Market Revenue and Forecast
10.1. B-Cell Lymphoma Market, by Route of Administration
10.1.1. Intravenous (IV)
10.1.1.1. Market Revenue and Forecast
10.1.2. Subcutaneous
10.1.2.1. Market Revenue and Forecast
10.1.3. Others
10.1.3.1. Market Revenue and Forecast
11.1. B-Cell Lymphoma Market, by End-User Setting
11.1.1. Hospitals
11.1.1.1. Market Revenue and Forecast
11.1.2. Specialty Clinics / Cancer Centers
11.1.2.1. Market Revenue and Forecast
11.1.3. Homecare Settings
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Disease Type
12.1.2. Market Revenue and Forecast, by Therapy Type
12.1.3. Market Revenue and Forecast, by Route of Administration
12.1.4. Market Revenue and Forecast, by End-User Setting
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Disease Type
12.1.5.2. Market Revenue and Forecast, by Therapy Type
12.1.5.3. Market Revenue and Forecast, by Route of Administration
12.1.5.4. Market Revenue and Forecast, by End-User Setting
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Disease Type
12.1.6.2. Market Revenue and Forecast, by Therapy Type
12.1.6.3. Market Revenue and Forecast, by Route of Administration
12.1.6.4. Market Revenue and Forecast, by End-User Setting
12.2. Europe
12.2.1. Market Revenue and Forecast, by Disease Type
12.2.2. Market Revenue and Forecast, by Therapy Type
12.2.3. Market Revenue and Forecast, by Route of Administration
12.2.4. Market Revenue and Forecast, by End-User Setting
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Disease Type
12.2.5.2. Market Revenue and Forecast, by Therapy Type
12.2.5.3. Market Revenue and Forecast, by Route of Administration
12.2.5.4. Market Revenue and Forecast, by End-User Setting
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Disease Type
12.2.6.2. Market Revenue and Forecast, by Therapy Type
12.2.6.3. Market Revenue and Forecast, by Route of Administration
12.2.6.4. Market Revenue and Forecast, by End-User Setting
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Disease Type
12.2.7.2. Market Revenue and Forecast, by Therapy Type
12.2.7.3. Market Revenue and Forecast, by Route of Administration
12.2.7.4. Market Revenue and Forecast, by End-User Setting
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Disease Type
12.2.8.2. Market Revenue and Forecast, by Therapy Type
12.2.8.3. Market Revenue and Forecast, by Route of Administration
12.2.8.4. Market Revenue and Forecast, by End-User Setting
12.3. APAC
12.3.1. Market Revenue and Forecast, by Disease Type
12.3.2. Market Revenue and Forecast, by Therapy Type
12.3.3. Market Revenue and Forecast, by Route of Administration
12.3.4. Market Revenue and Forecast, by End-User Setting
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Disease Type
12.3.5.2. Market Revenue and Forecast, by Therapy Type
12.3.5.3. Market Revenue and Forecast, by Route of Administration
12.3.5.4. Market Revenue and Forecast, by End-User Setting
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Disease Type
12.3.6.2. Market Revenue and Forecast, by Therapy Type
12.3.6.3. Market Revenue and Forecast, by Route of Administration
12.3.6.4. Market Revenue and Forecast, by End-User Setting
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Disease Type
12.3.7.2. Market Revenue and Forecast, by Therapy Type
12.3.7.3. Market Revenue and Forecast, by Route of Administration
12.3.7.4. Market Revenue and Forecast, by End-User Setting
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Disease Type
12.3.8.2. Market Revenue and Forecast, by Therapy Type
12.3.8.3. Market Revenue and Forecast, by Route of Administration
12.3.8.4. Market Revenue and Forecast, by End-User Setting
12.4. MEA
12.4.1. Market Revenue and Forecast, by Disease Type
12.4.2. Market Revenue and Forecast, by Therapy Type
12.4.3. Market Revenue and Forecast, by Route of Administration
12.4.4. Market Revenue and Forecast, by End-User Setting
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Disease Type
12.4.5.2. Market Revenue and Forecast, by Therapy Type
12.4.5.3. Market Revenue and Forecast, by Route of Administration
12.4.5.4. Market Revenue and Forecast, by End-User Setting
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Disease Type
12.4.6.2. Market Revenue and Forecast, by Therapy Type
12.4.6.3. Market Revenue and Forecast, by Route of Administration
12.4.6.4. Market Revenue and Forecast, by End-User Setting
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Disease Type
12.4.7.2. Market Revenue and Forecast, by Therapy Type
12.4.7.3. Market Revenue and Forecast, by Route of Administration
12.4.7.4. Market Revenue and Forecast, by End-User Setting
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Disease Type
12.4.8.2. Market Revenue and Forecast, by Therapy Type
12.4.8.3. Market Revenue and Forecast, by Route of Administration
12.4.8.4. Market Revenue and Forecast, by End-User Setting
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Disease Type
12.5.2. Market Revenue and Forecast, by Therapy Type
12.5.3. Market Revenue and Forecast, by Route of Administration
12.5.4. Market Revenue and Forecast, by End-User Setting
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Disease Type
12.5.5.2. Market Revenue and Forecast, by Therapy Type
12.5.5.3. Market Revenue and Forecast, by Route of Administration
12.5.5.4. Market Revenue and Forecast, by End-User Setting
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Disease Type
12.5.6.2. Market Revenue and Forecast, by Therapy Type
12.5.6.3. Market Revenue and Forecast, by Route of Administration
12.5.6.4. Market Revenue and Forecast, by End-User Setting
13.1. Roche
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Pfizer
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Bristol Myers Squibb
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Gilead Sciences
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Novartis
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. AbbVie
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. AstraZeneca
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Takeda Pharmaceutical
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Merck KGaA
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Seagen (Pfizer subsidiary)
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description